Abstract
Abstract 4962
Background: Burkits's like (BL) lymphoma is a new pathologic entity with features partially resembling to Burkitt's lymphoma and diffuse large B cell lymphoma. The incidence of BL lymphoma is infrequent and may present with lymph node enlargement, involvement of bone marrow and peripheral blood. The natural history of BL lymphoma and its treatment remains unclear. Here we present a single institution case series of five patients diagnosed with BL lymphoma and their treatment. Methods: We searched the pathology reports of all patients diagnosed with lymphoma over the last one year. No inclusion or exclusion criteria were used. Results: We identified a total of five patients with diagnosis of BL lymphoma. All patients presented with lymphadenopathy and with no involvement of bone marrow, central nervous system or peripheral blood. Table 1 summarizes characteristics of all patients, their chemotherapy regimen and subsequent response to treatment. Conclusion: BL lymphoma is a new pathologic entity with low incidence. Treatment with DA-EPOCH and R-HyperCVAD has very good response rate. The data is limited by single institution case series and limited follow up time. Further studies are recommended to evaluate optimal chemotherapy regimen. Table 1: Characteristics, presentation, treatment and response in patients with BL lymphoma
| No . | Age . | Sex . | LDH, . | Presentation . | Treatment . | Response . | Duration of response . |
|---|---|---|---|---|---|---|---|
| 1 | 68 | F | 386 | Parotid and abdominal lymphadenopathy | DA-R-EPOCH | CR | 16months |
| 2^ | 44 | M | 536 | Neck, Axillary, media, abdomen pelvis and sacral mets | R-HyperCVAD | PR | 3months |
| 3* | 66 | F | 310 | Inguinal and pelvic lymphadenopathy | R-HyperCVAD f/b Autologus BMT, | CR | 14months |
| 4** | 71 | M | 237 | Parotid mass | 3 cycles of DA-EPOCH f/b 3 cycles of R-CHOP | CR | 9months |
| 5^ | 52 | M | 186 | Neck Lymphadenopathy | R-HyperCVAD | CR | 3months |
| No . | Age . | Sex . | LDH, . | Presentation . | Treatment . | Response . | Duration of response . |
|---|---|---|---|---|---|---|---|
| 1 | 68 | F | 386 | Parotid and abdominal lymphadenopathy | DA-R-EPOCH | CR | 16months |
| 2^ | 44 | M | 536 | Neck, Axillary, media, abdomen pelvis and sacral mets | R-HyperCVAD | PR | 3months |
| 3* | 66 | F | 310 | Inguinal and pelvic lymphadenopathy | R-HyperCVAD f/b Autologus BMT, | CR | 14months |
| 4** | 71 | M | 237 | Parotid mass | 3 cycles of DA-EPOCH f/b 3 cycles of R-CHOP | CR | 9months |
| 5^ | 52 | M | 186 | Neck Lymphadenopathy | R-HyperCVAD | CR | 3months |
DOX, DOXOL, and anthracenediones in soluble fractions of human myocardial strips after sequential DOX loading/clearance and anthracenedione treatment
Notes: DA-REPOCH: Dose Adjusted Rituximab-Etoposide, Vincristine, Cyclophosphamide, Doxorubicine, Prednisone, R-HyperCVAD: Rituximab, hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, CR: complete remission, BMT: bone marrow transplantation, R-CHOP: rituximab, doxorubicin, cyclophosphamide, vincristine and prednisone. CNS: central nervous system
patient underwent bone marrow transplant because of relapse at current presentation.
patient was changed from DA EPOCH to R-CHOP as patient was not able to tolerate EPOCH
Epatients are halfway through their treatment cycles and are actively getting treatment
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.
